DEUSG

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an different strength representations being used in the drug model. Presentation is attached to bottom of meeting notes here: https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual    Thanks to Australia for the feedback and presentation. Regards, Shane

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an additional 'BoSS Clinical Drug' concept potentially being added to the drug model. Presentation on slide 22 here: https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view  and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on additional attributes being added to the MRCM for use in national drug extensions. Presentation here: https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence.ihtsdotools.org/

Proposal for change to medicinal products by changing the /1 hour normalization of patch products to usual manufacturer’s stated strength commonly /24 hours (or /1 hour or /16 hours or /72 hours may be appropriate). Do we have consensus in the DEUSG about how this should be represented in the international edition? For example, concentration strength (eg. moving away from normalized /1) or presentation strength - how would this work? - or something else (rate etc)? BN 20241007_ patches str

Please provide comments on the examples below representing the challenges in harmonizing the US Drug Extension with SNOMED CT international release introduced during the 2025-02-20 DEUSG meeting.  Complete details can be found at 2025-02-20: Virtual.  Slides can be found at: https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view. Recording starts at 55:00.   Summary of 5 examples: Thiothixene: SNOMED has